About Us

Singapore Clinical Research Institute (SCRI)

Established in 2008, the Singapore Clinical Research Institute (SCRI) was set up as the national academic clinical research organisation to enhance the standards of clinical research in Singapore by developing core capabilities, infrastructure and scientific leadership for clinical research.

In 2021, SCRI was appointed as the national coordinating body to implement the national clinical trial strategy and enhance Singapore’s clinical trial ecosystem.

This is accomplished through the deployment of innovative technologies and processes, and strategic coordination of ecosystem capabilities and infrastructure to achieve synergies that will enhance the clinical research ecosystem aimed towards a healthier community and better patient outcomes.

SCRI’s key pillars include:

1. Clinical Research Operations
2. Clinical Trials Infrastructure Coordination
3. Clinical Research Networks
4. Academic Research Partnerships
5. SCRI Academy

SCRI supports clinical trials and research in the domains of haematology and oncology, infectious diseases, ophthalmology, neuroscience, and cardiovascular.

SCRI stands as a business unit under the Consortium for Clinical Research and Innovation, Singapore (CRIS).

Consortium for Clinical Research and Innovation Singapore (CRIS)

CRIS or Consortium for Clinical Research and Innovation Singapore, was established in 2020 with the goal of strengthening synergies and developing strategies for national-level clinical research and translation programmes that are under the stewardship of the Ministry of Health. It is a subsidiary of MOH Holdings (MOHH).

CRIS aims to make a positive difference to Singapore patients and researchers by ensuring that these clinical research platforms and programmes are at the cutting edge of capability development and innovation. This will be achieved through facilitated collaborations and enduring partnerships with research and biomedical entities and communities across the public sector and industry across Singapore.

CRIS brings together six key national R&D initiatives and clinical services, and facilitate synergistic collaborations among them. These initiatives include:

1. Singapore Clinical Research Institute SCRI
2. National Health Innovation Centre Singapore NHIC
3. Advanced Cell Therapy and Research Institute, Singapore ACTRIS
4. Precision Health Research, Singapore PRECISE
5. Singapore Translational Cancer Consortium STCC
6. Cardiovascular Disease National Collaborative Enterprise CADENCE

Partners

CTSG deeply values its collaboration with esteemed partners, recognizing that our collective efforts pave the way for advancements in clinical research. We extend our heartfelt appreciation to all our partners for their contributions and shared vision in elevating the clinical trial landscape in Singapore.

---

STCC

The Singapore Translational Cancer Consortium (STCC) is a nationally coordinated consortium to synergise cancer research capabilities in Singapore.

Established in 2020, STCC brings together unmatched basic, clinical and translational talent in Singapore to create globally significant peaks of excellence in selected Asian cancers.

STCC’s joint platforms provide an enabling research and innovation environment driven to foster translational research with meaningful outcomes for society. These platforms are:

• Clinical Trials and Investigational Medicine Units
• Cancer Databases and Tissue Banks
• Translational Research Integration and Support
• Business Intelligence and Development

Through these forged collaborative relationships between local cancer research groups and by capitalising on the strengths of industry and academia, STCC is uniquely poised to develop initiatives that are aligned with Singapore’s goals in value-based healthcare innovation and economic value creation.

---

CADENCE

Established in February 2023, the CArdiovascular DiseasE National Collaborative Enterprise (CADENCE) is a national clinical translational programme aimed at synergising cardiovascular research and technology capabilities across Singapore.

Its goal is to integrate existing research capabilities, and bring together the strongest basic, clinical, and translational talent and expertise across Singapore and institutions, to become the leading Asian centre in CVD R&T.

CADENCE will establish four national joint platforms focused on data science, clinical trials, and artificial intelligence/digital health, together with a business intelligence and development unit to attract industry collaborations/external investments.

CADENCE is now in the first stage of implementation, focused on establishing operational capabilities of the four joint platforms.